ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /反応

Paclitaxel cephalomannine → Paclitaxel

HRID 992743
印刷

反応式

HRID 992743 の反応式
[CH3:1][C:2]1[C@@H:19]([O:20][C:21]([C@H:23]([OH:40])[C@@H:24]([NH:31][C:32]([C:34]2[CH:35]=[CH:36][CH:37]=[CH:38][CH:39]=2)=[O:33])[C:25]2[CH:26]=[CH:27][CH:28]=[CH:29][CH:30]=2)=[O:22])[CH2:18][C@:14]2([OH:41])[C:15]([CH3:17])([CH3:16])[C:3]=1[C@@H:4]([O:59][C:60]([CH3:62])=[O:61])[C:5]([C@@:7]1([CH3:58])[C@H:12]([C@@H:13]2[O:42][C:43]([C:45]2[CH:46]=[CH:47][CH:48]=[CH:49][CH:50]=2)=[O:44])[C@:11]2([O:53][C:54]([CH3:56])=[O:55])[CH2:51][O:52][C@@H:10]2[CH2:9][C@@H:8]1[OH:57])=[O:6].C/C=C(/C(N[C@H]([C@@H](O)C(O[C@@H]1C(C)=C2C(C)(C)[C@](O)([C@@H](OC(C3C=CC=CC=3)=O)[C@@H]3[C@]4(OC(C)=O)CO[C@@H]4C[C@H](O)[C@@]3(C)C([C@@H]2OC(C)=O)=O)C1)=O)C1C=CC=CC=1)=O)\C>ClCCl.CC(C)=O>[CH3:1][C:2]1[C@@H:19]([O:20][C:21]([C@H:23]([OH:40])[C@@H:24]([NH:31][C:32]([C:34]2[CH:39]=[CH:38][CH:37]=[CH:36][CH:35]=2)=[O:33])[C:25]2[CH:26]=[CH:27][CH:28]=[CH:29][CH:30]=2)=[O:22])[CH2:18][C@:14]2([OH:41])[C:15]([CH3:16])([CH3:17])[C:3]=1[C@@H:4]([O:59][C:60]([CH3:62])=[O:61])[C:5]([C@@:7]1([CH3:58])[C@H:12]([C@@H:13]2[O:42][C:43]([C:45]2[CH:50]=[CH:49][CH:48]=[CH:47][CH:46]=2)=[O:44])[C@:11]2([O:53][C:54]([CH3:56])=[O:55])[CH2:51][O:52][C@@H:10]2[CH2:9][C@@H:8]1[OH:57])=[O:6]
参加物実験手順後処理出典と根拠反応ノート

参加物

4

反応物 1

HCID 86586153Paclitaxel cephalomannine

生成物 1

HCID 36314Paclitaxel

試薬・触媒・溶媒 2

HCID 180Acetone溶媒HCID 6344Dichloromethane溶媒

実験手順

The paclitaxel/cephalomannine solid is dissolved in a minimum volume of dichloromethane or acetone and adsorbed onto a solid support such as silica gel or celite. According to the present invention the solid support is silica gel. The ratio of sample to solid support is about 1:1 to about 1:6 (w/w), preferably about 1:3. The sample is air dried to a free flowing powder and applied to 2 inch to 9 inch inner diameter glass or stainless steel columns previously loaded with silica gel in about 1:200 to 1:350 (w/w), preferably 1:250 ratio of sample to silica gel and equilibrated with mobile phase. The mobile phase is chosen from a mixture of toluene/ethyl acetate from about 7:3 to 1:1 (v/v) or toluene/dichloromethane/ ethyl acetate from about 5:1:3 to 2:1:2 (v/v/v) or other combinations of containing toluene having similar elutropic power. It is noteworthy to mention that the toluene in the mobile phase facilitates the separation of paclitaxel from cephalomannine, presumably due to π-π interaction of the toluene with the aromatic ring of paclitaxel. The column is eluted in an isocratic manner at a low pressure (about 5 to about 10 PSI). Eluant fractions (1L) are collected at a rate of 35 mL per minute and monitored by analytical tic and/or hplc. The fractions containing paclitaxel are pooled together and concentrated under reduced pressure to provide a solid residue, which is re-crystallized from a suitable solvent, including but not limited to hexane-acetone or aqueous methanol, to provide clinical standard paclitaxel (purity >98%).

後処理

  1. customdried to
  2. additionThe mobile phase is chosen from a mixture of toluene/ethyl acetate from about 7:3 to 1:1 (v/v) or toluene/dichloromethane/ ethyl acetate from about 5:1:3 to 2:1:2 (v/v/v) or other combinations of containing toluene having similar elutropic power
  3. customthe separation of paclitaxel from cephalomannine
  4. washThe column is eluted in an isocratic manner at a low pressure (about 5 to about 10 PSI)
  5. customEluant fractions (1L) are collected at a rate of 35 mL per minute
  6. additionThe fractions containing paclitaxel
  7. concentrationconcentrated under reduced pressure
  8. customto provide a solid residue, which
  9. customis re-crystallized from a suitable solvent

出典と根拠

ORDレコード
ord-ee2528ef38f844559b1ed859de0578fb
出典データセット
uspto-grants-2002_10
DOI
10.6084/m9.figshare.5104873.v1
特許番号
US06469186B1

反応ノート

このページの内容参加物実験手順後処理出典と根拠反応ノート